Dr. Charles Kore Kaufman - NPI #1003953613

Medical Oncologist located in Boston, MA

Massachusetts Boston Medical Oncology Dr. Charles Kore Kaufman Information


Dr. Charles Kore Kaufman is a male Medical Oncologist (taxonomy code 207RX0202X) located in Boston, Massachusetts. Dr. Charles Kore Kaufman primarily specializes in Medical Oncology but also specializes in and Internal Medicine. Dr. Charles Kore Kaufman's NPI Number is #1003953613 and has been listed in the NPI registry for 11 years. Dr. Charles Kore Kaufman's practice location is listed as: 450 Brookline Ave Boston, MA 02215-5418 and can be reached via phone at (617) 724-4000.

Medical Oncology Taxonomy

The taxonomy code for Dr. Charles Kore Kaufman's main specialty, Medical Oncology, is 207RX0202X. An internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer.



Be the first to rate Dr. Kaufman

Thanks for sharing your opinion!

‡ Descriptions, provider messages, and reviews are user submitted. While we make our best effort to verify the accuracy of information submissions, DocBios cannot guarantee that the information is accurate and/or up to date. Please verify any and/or all information with the provider. DocBios is not an advice or referral service and does not guarantee, approve, or endorse any particular healthcare provider.

Health Care Provider Information
 NPI # 1003953613
 Phone (617) 724-4000
 Fax Not Available
450 Brookline Ave
Boston, MA 02215-5418
 Gender M
 Website Not provided
  • Internal Medicine (MA)
  • Medical Oncology (MA)
Business Information
  • Sole Proprietor? Yes
  • Is Sub-Organization? Not Available
  • Parent Org Name: Not Available
 Updated 6/13/2011
 Added 1/31/2007
 Viewed on 4/23/2018
Health Care Providers Nearby

Thanks! Your edit was sucessfully submitted. Changes will be displayed after DocBios.com editors have reviewed your submission.